Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004000 | 0.92 | CTSS (0.43) | CTSSCTSKXDHRXRARXRG | |
| SCHEMBL18004159 | 0.91 | NOTUM (0.38) | CTSSCTSKDAONOTUMIKBKB | |
| SCHEMBL18004264 | 0.90 | RXRA (0.36) | CTSSCTSKDAORXRARXRG | |
| SCHEMBL18004161 | 0.89 | CNR1 (0.35) | CTSSCTSKRXRARXRGNOTUM | |
| SCHEMBL18004375 | 0.89 | MEN1 (0.37) | CTSSCTSKDAOTACR1CYP1A2 | |
| SCHEMBL18004247 | 0.85 | GPR52 (0.35) | NOTUM | |
| SCHEMBL18004391 | 0.85 | QPCT (0.33) | CTSSCTSK | |
| SCHEMBL18003937 | 0.85 | IDO1 (0.34) | CTSSCTSKDAOIDO1 | |
| SCHEMBL18004380 | 0.85 | LTA4H (0.35) | TACR1 | |
| SCHEMBL18003856 | 0.84 | CTSS (0.38) | CTSSCTSKXDHRXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CTSS 2273/4885CTSK 2390/4885DAO 732/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CTSS 2273/4885CTSK 2390/4885DAO 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.